Oral premedication with midazolam 7.5 mg was compared with temazepam 20 mg in a doubleblind study oJsixty patients undergoing day-stay urological surgery. One hour following ingestion similar degrees of anxiolysis and sedation were reported by patients for both compounds. However, midazolam was observed by anaesthetists to produce the greater anxiolytic effect and was given the better overall assessment. Midazolam produced significantly greater amnesia both at the time oJ induction and 30 minutes postoperatively. At the time of discharge four hours postoperatively no significant difference could be observed in psychomotor performance or subjective sedation although on the evening of surgery the temazepam group had a greater incidence of sleepiness and an earlier time to retiring. Although the differences were small, the residual post-discharge effects oftemazepam lead us to conclude that midazolam 7.5 mg is the more suitable premedicant for outpatient use.
Midazolam is a rapidly acting oral benzodiazepine with a time to peak effect of thirty minutes 2 . 3 and a short elimination half life of two hours. 8 ,9 The pharmacokinetic profile of midazolam suggests that it may be a useful premedicant, particularly in the day case setting, without the theoretical disadvantages of longer elimination half-life compounds. However, in a recent study of benzodiazepine premedication we observed that the sedation from midazolam 15 mg was excessive both in intensity and duration for day-case use lO and a similar conclusion was reached in one recent study from the United Kingdom. I I Because a dose of 15 mg midazolam was considered too large for day-case premedication, we examined in this present study the suitability of a lower dose, 7.5 mg and compared this with the already established premedicant temazepam 20 mg.
METHODS
The study was carried out on sixty patients pr~senting for day-stay urological surgery usmg a protocol identical to that used previously.lo Criteria for entry into the study were age 20-60 years, ASA grade 1-11 and no recent ingestion of psychotropic medication. The protocol was approved by the local ethical committee and informed consent was obtained from all patients.
One hour prior to scheduled surgery patients received either midazolam 7.5 mg or temazepam 20 mg (soft gelatin capsules) from coded envelopes in a randomised doubleblind manner. Compounds were administered with water by a nurse who was otherwise not involved with the study.
Intravenous induction of anaesthesia was achieved in all patients with a 10 mg/ml solution of methohexitone given incrementally, until loss of lash reflex followed by fentanyl 1.0 Ilg/kg. Anaesthesi~ was maintained with nitrous oxide 70% in oxygen and halothane, 0.5% increments as required, via a circle absorption system.
Immediately prior to premedication and again immediately before induction of anaesthesia, preoperative anxiety was assessed by the patient using a 100 mm linear analogue scale (LAS), the extremes of which were denoted at 0 mm 'extremely anxious' and at 100 mm 'not at all anxious'. Sedation, psychomotor performance and amnesia were assessed using a 100 mm LAS (0 mm 'wide awake, alert', 100 mm 'very drowsy, dull'), a letter deletion test and the showing of simple line diagrams for recall at 24 hours respectively. These tests were administered ~efore. premedication, immediately prior to mductIOn of anaesthesia and at 30 minutes 2 hours and 4 hours postoperatively.
' At the time of induction, the anaesthetist using a series of LAS, recorded his perceptio~ of the patient's degree of anxiety, quantity of oral secretions when inserting a Guedel airway and the severity of pain on injection and invoh.~ntary muscle movements following methohexltone. Overall ease of anaesthesia and impression of premedication were also assessed at the end of anaesthesia.
At the time of discharge four hours postoperatively, patients were seen by another anaesthetist who assessed the degree of sedation on an LAS, and degree of sway using Romberg's test. The recovery room nursing staff assessed overall quality of recovery on an LAS and recorded any postoperative side effects of anaesthesia.
Prior to discharge and on the day following surgery patients completed a questionnaire to assess the quality of their recovery, attitudes towards their premedication and possible side-effects resulting from it.
Statistical analysis of non-parametric data was performed using a chi squared test for categorical data and a Mann-Whitney 1I test for ordinal data. LAS assessments and letter deletion tests completed by the patient and physiological data were analysed by analysis of covariance (AN COY A) with the covariate taken as the unpremedicated value.
RESULTS
Patient demographic data is shown in Table  1 . The two groups of patients were of comparable age, weight and sex. The mean duration of anaesthesia was 10 (SD 6) minutes fo~ the temazepam group and 13 (SD 4) mmutes for the midazolam group (P < 0.05).
This difference was not due to the nature of the procedures undertaken and we feel it is not likely to have materially affected comparison of the premedication data.
The change in patient assessed LAS sedation and anxiety scores from before to one hour after premedication are shown in Figure  1 . Figure 2 plots the change in mean LAS sedation scores from the unpremedicated values throughout the perioperative period Table 2 records the anaesthetists' and nurses' assessments.
Anxio/ysis
At one hour there was a significant decrease in patient assessed preoperative anxiety with both compounds (P < 0.05) but no difference between the two drugs (P = 0.24). The anaesthetists' LAS assessment of anxiety showed that midazolam was perceived to produce the greatest anxiolysis (P < 0.005).
No difference was found when patients were asked if the premedicant made them 'feel better' or 'took away their anxiety' on the 4and 24-hour questionnaires.
Subjective sedation
Following anaesthesia there was no significant difference in the time to open eyes on command or in patient assessed LAS sedation scores at the time of induction, at 30 minutes, 2 hours or 4 hours postoperatively.
At the time of discharge 4 hours postoperatively no difference was found In 2.1 (2.5) number in the temazepam group, however, retired 'earlier than is usual in the evening' (15 versus 6, P < 0.01) and felt sleepy at home (12 versus 6, ns). Assessment of sedation by the anaesthetist at 4 hours showed no difference between the groups. Amnesia A greater reduction in the recall of simple line diagrams was found for midazolam immediately prior to induction and at 30 minutes postoperatively (P < 0.05). There was no difference in the recall of the anaesthetic induction at 24 hours although recall of pain on injection was less for those receiving midazolam (10 versus 20, P < 0.05).
Postoperative performance
No significant difference between the groups was found in the letter deletion test at any pre-or postoperative time and there were no differences in the patients' perceived ability to 'drive a car or motorcycle' or 'perform day to day work activities' at the time of discharge. Three patients in the midazolam group and two in the temazepam group felt they had difficulties getting home Anaesthesia and Intensive Care. Vol. 17. No. 2. Ma)·. /989 because of sleepiness, unsteadiness or other reasons.
Anaesthesia
The induction dose of methohexitone was identical in both groups (1.71 mg/kg) and no differences were noted in the observed incidence of pain on injection, muscle movement or hiccough after methohexitone injection. The anaesthetists' reported ease of anaesthesia was not significantly different.
Overall assessment of premedicants
Anaesthetists rated both premedicants highly at the time of induction, with midazolam being rated significantly better than temazepam (mean LAS score 8.3 cm vs 7.1 cm, P < 0.05 where 0 cm = very poor, inappropriate and 10 cm = excellent, appropriate). When asked whether they would be willing to prescribe the same premedicant again the response was affirmative in 90% for the midazolam group and 80% for temazepam (not significant).
When patients were asked whether they were happy to receive the same premedicant again, both compounds were rated highly, with 87% and 89% of responses being affirmative for midazolam and temazepam respectively.
DISCUSSION
In this study we found midazolam 7.5 mg and temazepam 20 mg to be acceptable daycase premedicants with both compounds showing comparable and significant anxiolytic and sedative effects. Midazolam was felt by anaesthetists to give the greatest anxidlytic effect and was given the best overall assessment.
Although midazolam was noted to produce greater amnesia than temazepam at the time of induction and immediately following the procedure, other measures of sedation revealed no difference between the medications up to four hours postoperatively. The 24-hour questionnaire however suggested that significantly more patients in the temazepam group had post-discharge sleepiness, an effect which might be predicted from the pharmacokinetic profile of the two compounds and a feature which was not noted in previous studies of temazepam which did not extend beyond the immediate postoperative period. 2 . 3 .4,11 Anaesthesia and Intensive Care, Vol. 17, No. ], May, 1989 Midazolam 7.5 mg did not cause the excessive sedation and amnesia extending into the postoperative period found in our previous study. 10 This result is consistent with a report from Nightingale and Norman l2 which, comparing midazolam 15 mg with temazepam 20 mg found the midazolam to be significantly more sedating than the temazepam although questionnaires returned the following day did not reveal any differences between the two compounds.
Another study comparing placebo with midazolam 7.5 mg or 15 mg observed that the 7.5 mg dose was ineffective in comparison with placebo with only the 15 mg dose producing significant anxiolysis and sedation. I I Taken together, these results suggest that 15 mg ofmidazolam is excessive for day-case use, the 7.5 mg dose is satisfactory but may be only marginally better than placebo, and temazepam 20 mg results in significant residual effects at 6 hours postpremedicationl 2 and, in our study, subjective sleepiness on the evening of surgery.
Previously we have observed that a range of anxiolytics including midazolam 15 mg were not significantly more anxiolytic than placebo. In this present study we did not incorporate a placebo group in the study design because we do not believe that a compound which cannot be differentiated from placebo is by definition of no clinical value. Placebo may itself be an acceptable premedicant and is of particular value in the relief of pain and anxiety. If it were possible to administer placebo as a day-case premedicant we would argue that it could be an acceptable option for routine use. However, if one was to administer a placebo in the clinical setting it would no longer be the same compound as could be administered in a double-blind study, becoming instead a single-blind placebo, with medical and nursing staff correspondingly altering their attitudes towards the medication. On the other hand a drug such as a benzodiazepine does not lose its pharmacological or placebo activity on becoming single-blind. It can therefore be argued that a placebo should be used for establishing pharmacological activity of a compound and an unpremedicated control should be used for establishing the clinical value and dose of the compound under examination.
In conclusion, preoperative midazolam 7.5 mg and temazepam 20 mg produced similar degrees of anxiolysis and sedation, with midazolam producing a more intense amnesic effect and temazepam resulting in a greater degree of residual sleepiness following discharge. In concert with a better overall assessment and perceived anxiolytic effect by anaesthetist, the results suggest that midazolam 7.5 mg may be superior to temazepam 20 mg as a day-case premedicant.
